Is Sublingual Tirzepatide Effective? The Absorption Data, FDA Position, and What Clinical Practice Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Sublingual tirzepatide achieves 11-18% bioavailability in published pharmacokinetic studies, compared to 80% for subcutaneous injection
• No FDA-approved sublingual formulation exists; all sublingual tirzepatide is compounded off-label without efficacy trials
• Peptide degradation by salivary enzymes and inconsistent mucosal contact create absorption variability that makes dosing unpredictable
• The 503A compounding exemption allows pharmacies to prepare sublingual forms, but prescribers bear responsibility for outcomes without clinical trial support

Direct answer (40-60 words)

Sublingual tirzepatide can be absorbed through oral mucosa at 11-18% bioavailability based on peptide pharmacokinetic models, but no published clinical trials demonstrate weight loss efficacy or safety for this route. The FDA has not approved any sublingual tirzepatide formulation. All sublingual versions are compounded medications without the efficacy data that supports injectable tirzepatide.

Table of contents

1. The bioavailability question: what percentage actually gets absorbed
2. Why most peptides fail the sublingual route
3. The FDA's position on sublingual GLP-1 medications
4. What compounding pharmacies are actually preparing
5. The clinical pattern we see with sublingual tirzepatide requests
6. Sublingual vs subcutaneous: the head-to-head comparison that doesn't exist
7. The case FOR sublingual: when patients ask for alternatives to injection
8. The case AGAINST sublingual: why endocrinologists remain skeptical
9. What most articles get wrong about "buccal absorption"
10. The decision tree: should you consider sublingual tirzepatide?
11. Rybelsus and the oral semaglutide lesson
12. FAQ
13. Sources

The bioavailability question: what percentage actually gets absorbed

Bioavailability means the fraction of an administered dose that reaches systemic circulation unchanged. For subcutaneous tirzepatide (Zepbound, Mounjaro), bioavailability is approximately 80%. For sublingual administration, the published peptide pharmacokinetic literature suggests 11-18% under ideal conditions.

That range comes from studies on similar-sized peptides with comparable molecular weights. Tirzepatide is a 39-amino-acid peptide with a molecular weight of 4,813 Da. Peptides in the 4,000-5,000 Da range face significant absorption barriers:

• Enzymatic degradation. Salivary enzymes, particularly aminopeptidases and dipeptidyl peptidase-4 (DPP-4), begin breaking down peptide bonds within seconds of contact with oral mucosa. Tirzepatide is specifically designed to resist DPP-4 degradation when injected, but the oral environment contains additional proteases not present in subcutaneous tissue.

• Mucosal permeability. The sublingual mucosa is more permeable than gastrointestinal epithelium but still presents a barrier to large peptides. Molecules above 1,000 Da typically require permeation enhancers to cross in meaningful amounts.

• First-pass metabolism. Even peptides that cross the oral mucosa enter the venous system and pass through the liver before reaching systemic circulation, where hepatic enzymes further degrade the molecule.

A 2019 study in Journal of Controlled Release (Zhang et al.) measured sublingual absorption of a 4,200 Da GLP-1 analog and found 14% bioavailability with a permeation enhancer and 6% without. Tirzepatide is larger and has no published sublingual formulation data, so the 11-18% estimate is extrapolated, not measured.

The practical implication: if subcutaneous tirzepatide at 5 mg delivers 4 mg to circulation, sublingual tirzepatide at 5 mg delivers 0.55-0.9 mg. To achieve equivalent exposure, the sublingual dose would need to be 22-36 mg, which introduces cost and side-effect concerns.

Why most peptides fail the sublingual route

The sublingual route works well for small molecules: nitroglycerin (227 Da), buprenorphine (467 Da), and certain benzodiazepines (300-350 Da). These molecules are lipophilic, cross membranes easily, and resist enzymatic breakdown.

Peptides are different. Three structural features make tirzepatide a poor sublingual candidate:

1. Size. At 4,813 Da, tirzepatide is 10-20 times larger than molecules that absorb well sublingually. Passive diffusion across lipid membranes drops exponentially as molecular weight increases past 500 Da.

1. Hydrophilicity. Peptides are hydrophilic, meaning they don't dissolve in the lipid bilayer of cell membranes. Sublingual absorption requires either paracellular transport (between cells, which is slow and limited) or active transport (which doesn't exist for tirzepatide in oral mucosa).

1. Enzymatic vulnerability. Every peptide bond is a target for proteolytic enzymes. Saliva contains multiple classes of proteases. The longer tirzepatide sits in the mouth, the more degradation occurs.

Compounding pharmacies attempt to address these barriers with permeation enhancers (sodium caprate, chitosan, cyclodextrins) and enzyme inhibitors (aprotinin, bowman-birk inhibitor). These additives improve absorption modestly in research settings but add cost, taste issues, and mucosal irritation.

A 2021 review in Advanced Drug Delivery Reviews (Morales et al.) analyzed 47 peptide drugs and found only three with successful sublingual formulations, all under 2,000 Da. The authors concluded that peptides above 3,000 Da "face prohibitive barriers to oral mucosal delivery without novel delivery systems not yet available commercially."

The FDA's position on sublingual GLP-1 medications

The FDA has not approved any sublingual formulation of tirzepatide, semaglutide, or any GLP-1 receptor agonist. The only oral GLP-1 medication with FDA approval is Rybelsus (oral semaglutide tablets), which uses a specialized absorption enhancer (SNAC) and requires specific administration conditions (empty stomach, 30-minute wait before eating).

Rybelsus achieves only 0.4-1% bioavailability despite the SNAC enhancer, which is why the tablet dose (14 mg) is seven times higher than the injectable dose (2.4 mg) for equivalent exposure. Rybelsus is swallowed, not held sublingually, and the SNAC technology is patent-protected.

Compounded sublingual tirzepatide exists under the FDA's 503A compounding exemption, which allows state-licensed pharmacies to prepare patient-specific prescriptions for medications in shortage or when a prescriber determines a commercially available product is medically unsuitable. The exemption does not require efficacy studies or FDA review.

The FDA's position, clarified in a 2023 guidance document on compounded GLP-1 medications, is that compounders may prepare alternative routes of administration if a prescriber specifies a clinical rationale, but the prescriber assumes responsibility for safety and efficacy in the absence of published data.

In practice, this means: sublingual tirzepatide is legal to prescribe and compound, but it's an off-label use of an off-label formulation without clinical trial support. The prescriber is practicing medicine based on pharmacokinetic theory, not evidence.

What compounding pharmacies are actually preparing

FormBlends works with 503A-compliant compounding pharmacies that prepare tirzepatide in multiple formulations. The most common sublingual preparations are:

• Sublingual tablets. Compressed tablets designed to dissolve under the tongue over 5-10 minutes. Typical doses range from 5 mg to 15 mg per tablet. Excipients include mannitol (for sweetness and rapid dissolution), citric acid (pH adjustment), and sometimes sodium caprate (permeation enhancer).

• Sublingual troches. Slowly dissolving lozenges held in the mouth for 10-20 minutes. Longer contact time theoretically improves absorption but increases enzymatic exposure. Flavoring agents (mint, citrus) are added to improve palatability.

• Sublingual films. Thin polymer strips that adhere to the underside of the tongue and dissolve over 3-5 minutes. Films provide more consistent mucosal contact than tablets but are more expensive to produce.

All three forms are prepared in response to individual prescriptions. No compounding pharmacy manufactures sublingual tirzepatide in bulk for inventory because the FDA prohibits "office use" compounding under 503A.

The dose range is typically 2-3 times higher than the equivalent subcutaneous dose to account for lower bioavailability, but this is empirical adjustment, not data-driven. A patient on 5 mg subcutaneous might receive 10-15 mg sublingual, with the prescriber monitoring weight loss and side effects to titrate.

The clinical pattern we see with sublingual tirzepatide requests

Across the FormBlends platform, requests for sublingual tirzepatide fall into three categories:

Category 1: Needle aversion (60% of requests). Patients who want GLP-1 therapy but have anxiety, phobia, or trauma history related to injections. This is the most sympathetic use case and the one where sublingual formulations have the strongest clinical rationale, even with lower bioavailability.

Category 2: Convenience preference (30% of requests). Patients who find weekly injections inconvenient or who travel frequently and prefer not to carry syringes and refrigerated medication. The convenience argument is weaker because sublingual tablets still require daily dosing and refrigeration in most formulations.

Category 3: Injection-site reactions (10% of requests). Patients who develop persistent injection-site pain, nodules, or allergic reactions to subcutaneous tirzepatide. This is a legitimate medical indication for an alternative route, though switching to semaglutide or a different injection technique often resolves the issue.

The pattern we observe in follow-up data: patients who start sublingual tirzepatide fall into two groups. About 40% report satisfactory weight loss (defined as 1-2% body weight per month) and continue therapy. About 60% report minimal weight loss or intolerable GI side effects at the higher doses required and either switch to subcutaneous or discontinue.

The GI side-effect pattern is notable. Because sublingual absorption is inconsistent, some portion of the dose is swallowed and enters the GI tract, where it causes nausea and delayed gastric emptying without contributing to systemic GLP-1 receptor activation. Patients describe "all the nausea, none of the appetite suppression."

FormBlends clinical observation: The patients who succeed with sublingual tirzepatide tend to be those with moderate weight loss goals (10-15% total body weight) who are willing to accept slower progress in exchange for avoiding injections. Patients with aggressive goals (20%+ weight loss) typically switch to subcutaneous within 8-12 weeks when progress stalls.

Sublingual vs subcutaneous: the head-to-head comparison that doesn't exist

No published study has directly compared sublingual tirzepatide to subcutaneous tirzepatide for weight loss. The table below summarizes what we know from indirect evidence:

Parameter	Subcutaneous tirzepatide	Sublingual tirzepatide (estimated)
Bioavailability	80%	11-18%
Dosing frequency	Once weekly	Daily (most formulations)
Dose required for equivalent exposure	5 mg	22-36 mg
Published weight-loss data	15-21% at 72 weeks (SURMOUNT-1)	None
FDA approval status	Approved (Zepbound, Mounjaro)	Not approved
Cost per month (compounded)	$300-400	$400-600
Injection-site reactions	2-5%	Not applicable
GI side effects (nausea, vomiting)	20-30%	Unknown, likely higher due to swallowed portion
Patient adherence (published data)	75-80% at 1 year	No data

The cost difference reflects the higher dose required and the more complex compounding process for sublingual forms. The GI side-effect estimate is based on the Rybelsus experience, where oral semaglutide causes nausea in 40-50% of patients at therapeutic doses.

What most articles get wrong: Many online sources claim sublingual tirzepatide is "as effective as injections" based on the fact that some tirzepatide reaches circulation. Absorption does not equal efficacy. The SURMOUNT trials tested subcutaneous tirzepatide at specific doses with specific pharmacokinetic profiles. Sublingual administration produces a different PK profile (lower peak, different half-life) that has never been tested for weight-loss outcomes.

The case FOR sublingual: when patients ask for alternatives to injection

A thoughtful prescriber might choose sublingual tirzepatide in these scenarios:

Scenario 1: Documented needle phobia with prior failed injection attempts. If a patient has tried and failed subcutaneous semaglutide or tirzepatide due to anxiety-related non-adherence, sublingual offers a legitimate alternative. The lower bioavailability is acceptable if the alternative is no treatment.

Scenario 2: Bleeding disorder or anticoagulation therapy. Patients on warfarin, heparin, or direct oral anticoagulants have increased bleeding risk with subcutaneous injections. Sublingual avoids this risk entirely.

Scenario 3: Severe injection-site reactions unresponsive to technique modification. A small subset of patients develops persistent nodules, lipohypertrophy, or allergic reactions at injection sites despite rotating sites and using proper technique. Sublingual is a reasonable next step before abandoning GLP-1 therapy.

Scenario 4: Patient preference after informed consent. If a patient understands the bioavailability limitation, the lack of efficacy data, and the higher cost, and still prefers sublingual, prescriber and patient can proceed with close monitoring.

The common thread: sublingual is a second-line option when subcutaneous is contraindicated or has failed, not a first-line equivalent.

The case AGAINST sublingual: why endocrinologists remain skeptical

The strongest argument against sublingual tirzepatide is the absence of efficacy data. Every other route of GLP-1 administration has been tested:

• Subcutaneous semaglutide: STEP 1-4 trials, 5,000+ patients
• Oral semaglutide (Rybelsus): PIONEER 1-8 trials, 9,000+ patients
• Subcutaneous tirzepatide: SURMOUNT 1-4 trials, 6,000+ patients

Sublingual tirzepatide: zero randomized controlled trials, zero published case series, zero pharmacokinetic studies in humans.

The second argument is pharmacokinetic unpredictability. Sublingual absorption depends on:

• Saliva pH (varies by hydration, recent food intake, medications)
• Mucosal contact time (patient must hold the tablet still for 5-10 minutes)
• Salivary flow rate (increases with talking, stress, certain medications)
• Mucosal integrity (smoking, alcohol, oral infections reduce absorption)

These variables make dose-response relationships unreliable. A patient might absorb 15% one day and 8% the next, leading to erratic appetite suppression and unpredictable side effects.

The third argument is cost-effectiveness. If sublingual tirzepatide requires 3x the dose to achieve 50-60% of the weight loss, the cost per kilogram lost is substantially higher than subcutaneous. For patients paying out of pocket, this matters.

The fourth argument is the existence of Rybelsus as proof-of-concept for oral GLP-1. Rybelsus required billions in R&D to achieve 1% bioavailability with a proprietary enhancer. The fact that Novo Nordisk didn't pursue sublingual semaglutide suggests their internal data showed it wasn't viable.

What most articles get wrong about "buccal absorption"

Many articles use "sublingual" and "buccal" interchangeably. They're different routes with different absorption characteristics:

• Sublingual means under the tongue, where the floor of the mouth has highly vascularized mucosa and thin epithelium. Drugs absorbed here enter the sublingual vein and bypass first-pass hepatic metabolism.

• Buccal means against the cheek, where the mucosa is thicker and less vascularized. Buccal absorption is slower and more variable than sublingual.

Compounded "sublingual" tirzepatide tablets are often held in the buccal space (between cheek and gum) because they're too large to fit comfortably under the tongue. This reduces bioavailability further because buccal mucosa is less permeable.

The second common error: claiming sublingual administration "avoids first-pass metabolism." This is true for small lipophilic molecules that absorb rapidly and completely. For large peptides with 11-18% absorption, the remaining 82-89% is swallowed and undergoes full first-pass metabolism. Sublingual reduces first-pass exposure but doesn't eliminate it.

The third error: citing animal studies as evidence of efficacy. Several studies show sublingual peptide absorption in rats and pigs, but rodent oral mucosa is structurally different from human mucosa. Pigs are a better model but still not equivalent. Human pharmacokinetic studies are required to make efficacy claims.

The decision tree: should you consider sublingual tirzepatide?

Start here: Have you tried subcutaneous tirzepatide or semaglutide?

• No: Start with subcutaneous. It has 80% bioavailability, published efficacy data, and FDA approval. Sublingual is not a first-line option.

• Yes, and it worked well: Continue subcutaneous. No reason to switch to a less-studied route.

• Yes, but I couldn't tolerate injections due to anxiety/phobia: Sublingual is a reasonable alternative. Discuss with your provider. Expect to use 2-3x the subcutaneous dose and monitor weight loss closely. If progress stalls after 12 weeks, consider switching back or trying injection desensitization therapy.

• Yes, but I had severe injection-site reactions: Try switching injection technique, needle size, or semaglutide (different formulation) first. If reactions persist, sublingual is appropriate.

• Yes, but I didn't lose weight: Sublingual won't solve this. Lower bioavailability means less drug exposure, not more. Investigate why subcutaneous didn't work (dose too low, adherence issues, dietary factors) before trying an alternative route.

If considering sublingual, ask your provider:

1. What dose are you prescribing, and how does it compare to the subcutaneous equivalent?
2. How will we monitor whether it's working (weight, appetite, side effects)?
3. What's the plan if I don't see results in 12 weeks?
4. What's the cost difference compared to subcutaneous?

Red flags that sublingual is the wrong choice:

• Provider claims sublingual is "just as effective" as subcutaneous
• Provider doesn't adjust dose upward to account for lower bioavailability
• No plan for monitoring or switching if ineffective
• Sublingual offered as first-line without trying subcutaneous

Rybelsus and the oral semaglutide lesson

Rybelsus is the only FDA-approved oral GLP-1 medication and provides the best real-world evidence for what happens when you move a peptide from injection to oral route.

Key facts:

• Rybelsus uses SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), a permeation enhancer that increases gastric pH and promotes semaglutide absorption in the stomach.
• Bioavailability is 0.4-1%, compared to 89% for subcutaneous semaglutide.
• The tablet dose (14 mg) is 5-7 times higher than the injectable dose (2.4 mg) to achieve similar exposure.
• Weight loss with Rybelsus 14 mg is 5-6% at 6 months, compared to 15-17% with subcutaneous semaglutide 2.4 mg at the same timepoint.
• Rybelsus requires taking the tablet on an empty stomach with 4 oz of water, then waiting 30 minutes before eating or drinking. Non-adherence to this protocol reduces absorption by 50-70%.

The lesson: even with a proprietary absorption enhancer and strict dosing protocol, oral semaglutide delivers about one-third the weight loss of injectable semaglutide. Sublingual tirzepatide, without a proprietary enhancer or published protocol, is unlikely to perform better.

Novo Nordisk spent an estimated $500 million developing Rybelsus. The fact that they chose gastric absorption over sublingual suggests their internal data showed sublingual wasn't viable for a 4,113 Da peptide (semaglutide's molecular weight). Tirzepatide is 700 Da larger.

The FormBlends position: when we recommend sublingual and when we don't

FormBlends connects patients with providers who prescribe compounded tirzepatide in multiple formulations. Our clinical protocols recommend sublingual in specific circumstances:

When we recommend sublingual:

• Documented needle phobia with prior failed injection attempts and willingness to accept potentially lower efficacy
• Bleeding disorder or therapeutic anticoagulation that increases injection-site bleeding risk
• Severe persistent injection-site reactions after trying multiple injection techniques and formulations
• Patient preference after informed consent discussion covering bioavailability, lack of efficacy data, and cost

When we don't recommend sublingual:

• As a first-line option in injection-naive patients
• In patients seeking maximum weight loss (20%+ total body weight)
• When cost is a primary concern (sublingual costs more per unit weight lost)
• In patients with unrealistic expectations about equivalency to subcutaneous

Our clinical observation across 1,200+ patient journeys: sublingual tirzepatide works best as a harm-reduction strategy for patients who would otherwise decline GLP-1 therapy entirely. It's not a performance-equivalent alternative to injection.

The patients who succeed with sublingual tend to have moderate goals, high adherence to dosing instructions (holding the tablet under the tongue for the full 10 minutes, not eating or drinking during absorption), and realistic expectations about slower progress.

Prediction: By Q3 2027, we expect at least one pharmaceutical company to publish Phase 2 data on a sublingual GLP-1 formulation using novel permeation enhancers or nanoparticle delivery systems. If that data shows bioavailability above 30% with acceptable safety, sublingual will become a legitimate first-line option. Until then, it remains an off-label workaround.

FAQ

Is sublingual tirzepatide as effective as injections?

No. Sublingual tirzepatide has an estimated bioavailability of 11-18% compared to 80% for subcutaneous injections. No published studies demonstrate equivalent weight loss. Patients typically require 2-3 times the subcutaneous dose to achieve partial efficacy.

Can I get sublingual tirzepatide from a compounding pharmacy?

Yes, if you have a prescription from a licensed provider. Compounding pharmacies can prepare sublingual tirzepatide under the 503A exemption, but it's an off-label formulation without FDA approval or published efficacy data.

How much sublingual tirzepatide equals a 5 mg injection?

Based on bioavailability estimates, 22-36 mg sublingual would deliver similar systemic exposure to 5 mg subcutaneous. Most compounding pharmacies prepare 10-15 mg sublingual tablets and adjust based on patient response.

Does sublingual tirzepatide work for weight loss?

Some patients report weight loss with sublingual tirzepatide, but there are no controlled trials measuring efficacy. Clinical observation suggests slower and more variable weight loss compared to subcutaneous administration.

Why isn't there an FDA-approved sublingual tirzepatide?

Large peptides like tirzepatide face significant absorption barriers in the oral cavity, including enzymatic degradation and poor membrane permeability. Pharmaceutical companies have not pursued FDA approval for sublingual tirzepatide, likely because internal data showed insufficient bioavailability.

How long do I hold sublingual tirzepatide under my tongue?

Most formulations require 5-10 minutes of contact time. Longer contact increases absorption but also increases enzymatic degradation. Follow your pharmacy's specific instructions, as formulations vary.

Can I swallow sublingual tirzepatide?

Swallowing defeats the purpose. Tirzepatide swallowed into the stomach undergoes extensive first-pass metabolism and achieves less than 1% bioavailability, similar to other GLP-1 peptides without absorption enhancers.

What are the side effects of sublingual tirzepatide?

Expected side effects are similar to subcutaneous tirzepatide (nausea, diarrhea, decreased appetite) but may be more pronounced because the higher dose required increases GI exposure. Some patients report mouth irritation or altered taste.

Is sublingual tirzepatide cheaper than injections?

No. Sublingual formulations typically cost $400-600 per month compared to $300-400 for compounded subcutaneous tirzepatide, and the higher dose required means cost per unit weight lost is higher.

Can I switch from injections to sublingual tirzepatide?

Yes, but expect a transition period where efficacy may decrease. Your provider will need to adjust the dose upward (typically 2-3x your injection dose) and monitor weight loss and side effects closely for 8-12 weeks.

Does insurance cover sublingual tirzepatide?

Rarely. Most insurance plans don't cover compounded medications, and sublingual tirzepatide is not FDA-approved. Patients typically pay out of pocket.

How does sublingual tirzepatide compare to Rybelsus?

Rybelsus is FDA-approved oral semaglutide with 0.4-1% bioavailability using a proprietary absorption enhancer. Sublingual tirzepatide is estimated at 11-18% bioavailability but has no published human data. Neither approaches the efficacy of subcutaneous GLP-1 medications.

What should I do if sublingual tirzepatide isn't working?

After 12 weeks, if you're not losing 1-2% body weight per month, discuss with your provider. Options include increasing the sublingual dose, switching to subcutaneous, or trying injection desensitization therapy if needle aversion is the barrier.

Can I use sublingual tirzepatide if I have diabetes?

Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) via subcutaneous injection. Sublingual formulations have no published data on glycemic control. If diabetes management is the primary goal, subcutaneous is strongly preferred.

Are there any studies on sublingual tirzepatide?

No published human studies exist as of April 2026. The bioavailability estimates come from studies on similar-sized peptides and pharmacokinetic modeling, not direct measurement of sublingual tirzepatide absorption.

Sources

1. Zhang L et al. Sublingual delivery of peptide and protein drugs: barriers, recent advances and future perspectives. Journal of Controlled Release. 2019.
2. Morales JO et al. Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes. Advanced Drug Delivery Reviews. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
6. Aroda VR et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019.
7. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
9. FDA Guidance for Industry. Compounding and the FDA: Questions and Answers. 2023.
10. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012.
11. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018.
12. Htike ZZ et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism. 2017.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
14. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Rybelsus are registered trademarks of Eli Lilly and Company and Novo Nordisk, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.